Therapeutic drug monitoring in pregnant and postpartum women: recommendations for SSRIs, lamotrigine, and lithium.
Deligiannidis
Kristina M
KM
Center for Psychopharmacologic Research and Treatment, 361 Plantation St, Worcester, MA 01605, USA. kristina.deligiannidis@umassmemorial.org
D000927:Anticonvulsants / Q000627:therapeutic use*; D018692:Antimanic Agents / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy; D016903:Drug Monitoring; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006801:Humans; D000077213:Lamotrigine; D018020:Lithium Compounds / Q000627:therapeutic use*; D049590:Postpartum Period / Q000187:drug effects*; D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D014227:Triazines / Q000627:therapeutic use*
D000927:Anticonvulsants; D018692:Antimanic Agents; D000077213:Lamotrigine; D018020:Lithium Compounds; D017367:Selective Serotonin Reuptake Inhibitors; D014227:Triazines